“The lotus leaf has given us a wonderful example of a self-cleaning system, designed by nature. ”

– Queen's chemist Dr. Guojun Liu on his amphiphobic materials


Queen's-developed solar energy technology recieves first U.S. patent

Dec. 15, 2004

KINGSTON, ON -- A novel solar heating technology developed at Queen's University has been granted a patent by the U.S. Patent and Trademark Office. 

U.S. Patent No. 6,827,091, for Passive Back-Flushing Thermal Energy System, was issued to Queen's earlier this month. 

The patented heating technology was invented by Dr. Stephen Harrison, Associate Professor of Mechanical Engineering at Queen's University, for application in a prototype solar hot water heater developed by EnerWorks, Inc., a London, Ontario-based alternative energy company. 

Robotic invention for assessing motor skills in stroke and spinal cord patients debuts at international conference

October 25, 2004

KINGSTON, ON – Neuroscientists from Queen’s will showcase a new robotic system for assessing the motor skills of people with stroke and spinal cord injuries at this week’s international Society for Neuroscience conference in San Diego.

The only device of its kind that measures multi-joint movement at the shoulder, elbow and hand, the patented KINARM is now available for both basic and clinical research on limb motor performance. Several studies using KINARM have already led to new findings about how the brain coordinates limb movements.

Queen's-discovered ethanol extraction process licensed to Xethanol Corp.

Oct. 19, 2004 

KINGSTON, ON - A novel extractive fermentation technology for the production of ethanol has been exclusively licensed to Xethanol Corporation by PARTEQ Innovations, the technology transfer arm of Queen's University. 

The patented technology, developed by Dr. Andrew Daugulis of the Department of Chemical Engineering at Queen's, allows for more efficient production of ethanol, a clean-burning renewable fuel used in gasoline blends to improve vehicle performance. 

Queen's University researchers issued 15 patents in 2003-2004

Aug. 25, 2004

KINGSTON, ON - A therapeutic approach for treating neurological conditions such as Alzheimer's disease, a method for enhancing plant growth, and a process for producing a dense, hard-wearing ceramic coating are among Queen's University-generated technologies that were issued a total of 15 patents during the 2003-2004 year, reports PARTEQ Innovations, the technology transfer arm of the university.

New organization to focus on technology transfer by Ontario's academic research institutions

June 21, 2004 

For immediate release 

KINGSTON, ON - PARTEQ Innovations, the technology transfer arm of Queen's University, has joined technology transfer offices at academic research institutions across Ontario in a new organization to promote the commercialization of innovative research. The Ontario Society for Excellence in Technology Transfer (onSETT) , representing universities, research hospitals and other institutions, will be the voice for technology transfer across Ontario. 

David Whiting appointed to board of Queen's University's PARTEQ Innovations

June 3, 2004 

For immediate release 

KINGSTON, ON -- PARTEQ Innovations, the technology transfer arm of Queen's University, is pleased to announce the appointment of Mr. David Whiting to its Board of Directors. 

Mr. Whiting is founder, president and majority shareholder of Merlan Scientific Ltd., an international developer and distributor of science, technology and engineering products for the educational sector. He is a member of Queen's Board of Trustees and is chair of the Strategic Planning Committee of the Queen's Alumni Association.

PARTEQ, McGill spinoff companies and NeuroSearch of Denmark join forces to address chronic pain

March 23, 2004

KINGSTON, ON – Neuroceptor, Inc., and Antalium Inc., spinoff companies of Queen's University and McGill University respectively, are pleased to announce their merger into a new company, PainCeptor Pharma Corporation. The company will operate from facilities in Montreal, Quebec and Kingston, Ontario. 

GB Therapeutics receives FDA approval to begin clinical trials of Alzheimer's candidate

Jan. 7, 2004
MISSISSAUGA, ON -- GB Therapeutics Ltd., a spinoff company of Queen's University's PARTEQ Innovations, has received approval from the U.S. Food and Drug Administration to begin human safety testing of GT 1061, its lead drug candidate targeting mild to moderate Alzheimer's disease.

GB Therapeutics received Canadian regulatory approval to begin Phase 1a testing in December, allowing the company to pursue a dual Canada/U.S. clinical strategy, says Anthony Giovinazzo, President and CEO. 

Subscribe to RSS - 2004